Cargando…

Plasmacytoid Dendritic Cells in Patients with MGUS and Multiple Myeloma

Background: Plasmacytoid dendritic cells (pDCs) play prominent roles in mediating innate and adaptive immune responses. However, it is unclear how pDCs contribute to the immunosuppressive tumor microenvironment described in multiple myeloma (MM). Methods: Newly diagnosed myeloma patients (MM, n = 37...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knight, Andrea, Rihova, Lucie, Kralova, Romana, Penka, Miroslav, Adam, Zdenek, Pour, Ludek, Piskacek, Martin, Hajek, Roman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396926/ https://www.ncbi.nlm.nih.gov/pubmed/34442012 http://dx.doi.org/10.3390/jcm10163717

Ejemplares similares

Functionally Suppressive CD8 T Regulatory Cells Are Increased in Patients with Multiple Myeloma: A Cause for Immune Impairment
por: Muthu Raja, Karthick Raja, et al.
Publicado: (2012)

Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple Myeloma
por: Muthu Raja, Karthick Raja, et al.
Publicado: (2012)

Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia
por: Bezdekova, Renata, et al.
Publicado: (2021)

Dynamics of tumor‐specific cfDNA in response to therapy in multiple myeloma patients
por: Vrabel, David, et al.
Publicado: (2019)

Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma
por: Besse, Lenka, et al.
Publicado: (2015)

Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma
por: Kubiczkova, Lenka, et al.
Publicado: (2014)

Active multiple myeloma suppresses and typically eliminates coexisting MGUS
por: Campbell, John P, et al.
Publicado: (2017)

Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma
por: Vlachová, Monika, et al.
Publicado: (2022)

Genome-Wide Screening of Cytogenetic Abnormalities in Multiple Myeloma Patients Using Array-CGH Technique: A Czech Multicenter Experience
por: Smetana, Jan, et al.
Publicado: (2014)

A gene signature can predict risk of MGUS progressing to multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2023)

PB2073: EVALUATION OF THE PLASMA METABOLOMIC PROFILE OF MGUS AND MULTIPLE MYELOMA PATIENTS
por: Ciesluk, Klaudia, et al.
Publicado: (2023)

Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2013)

Centrosome associated genes pattern for risk sub-stratification in multiple myeloma
por: Kryukov, Fedor, et al.
Publicado: (2016)

More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma
por: Jelinek, Tomas, et al.
Publicado: (2023)

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine
por: Zátopková, Martina, et al.
Publicado: (2022)

PB2072: CIRCULATING CD71+ MYELOID PRECURSORS IN MGUS AND MULTIPLE MYELOMA: A PROSPECTIVE SURVEY
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma
por: Ludwig, C, et al.
Publicado: (2015)

Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients
por: Lamanuzzi, Aurelia, et al.
Publicado: (2016)

Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability
por: Dutta, Ankit K., et al.
Publicado: (2018)

Ulcerating necrobiotic xanthogranuloma: A clinical sign to reconsider progression from MGUS to multiple myeloma
por: Fay, Christopher J., et al.
Publicado: (2023)

MGUS bone
por: Imataki, Osamu, et al.
Publicado: (2019)

Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients
por: Bosseboeuf, Adrien, et al.
Publicado: (2020)

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
por: Visram, A., et al.
Publicado: (2021)

Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma
por: Hájek, Roman, et al.
Publicado: (2019)

Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience
por: Krejci, Marta, et al.
Publicado: (2021)

Identification of patients at high risk of secondary extramedullary multiple myeloma development
por: Stork, Martin, et al.
Publicado: (2021)

Inheritance in MGUS and MM
por: Pfreundschuh, Michael
Publicado: (2015)

Clinical and Biological Implications of MYC Activation: A common difference between MGUS and newly diagnosed multiple myeloma
por: Chng, WJ, et al.
Publicado: (2011)

Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma
por: Schneiderova, Petra, et al.
Publicado: (2016)

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
por: Rodríguez-Otero, Paula, et al.
Publicado: (2019)

Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr Virus EBNA-1
por: Bosseboeuf, Adrien, et al.
Publicado: (2020)

CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma
por: Thangavadivel, Shanmugapriya, et al.
Publicado: (2016)

Long Non-Coding RNAs in Multiple Myeloma
por: Butova, Romana, et al.
Publicado: (2019)

Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network
por: op Bruinink, Davine Hofste, et al.
Publicado: (2020)

Do human B-lymphocytes avoid aging until 60 years?
por: Knight, Andrea, et al.
Publicado: (2016)

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
por: Stork, Martin, et al.
Publicado: (2022)

Multiple Myeloma Plasmacytoid Infiltration of the Gallbladder Presenting as Acute Cholecystitis
por: Alyass, Fadi, et al.
Publicado: (2021)

Multiple myeloma in a kidney transplanted patient primarily diagnosed with monoclonal gammopathy of unknown significance (MGUS)-related nephropathy
por: Resuli, Marsela, et al.
Publicado: (2013)

Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients
por: Steiner, Normann, et al.
Publicado: (2017)

Mass Cytometry Discovers Two Discrete Subsets of CD39(−)Treg Which Discriminate MGUS From Multiple Myeloma
por: Marsh-Wakefield, Felix, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4up02cps11rgidgvupjfju0gu7